Transgene(DE:TGNA)
€0.71+0.01 (+0.86%)
DE:TGNA
Transgene stock drug pipeline
€0.71
At close:+0.01 (+0.86%)
Transgene (TGNA) Drug Pipeline
0 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Tg6050 | Non-small Cell Lung Cancer | Phase I | Terminated | A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir) | Mar 15, 2023 | ― |
| Tg4050 | Squamous Cell Carcinoma Of Head And Neck | phase1AndPhase2 | Active Not Recruiting | A Clinical Trial Evaluating TG4050 in Head and Neck Cancer | Nov 21, 2019 | ― |
| Tg4050 | Fallopian Tube Cancer, Ovarian Carcinoma, Peritoneal Carcinoma | Phase I | Completed | A Trial Evaluating TG4050 in Ovarian Carcinoma. | Feb 06, 2019 | ― |
| Avelumab, Tg4001 | Hpv-Related Cervical Carcinoma, Hpv-Related Carcinoma, Hpv-Related Anal Squamous Cell Carcinoma, Hpv-Related Penile Squamous Cell Carcinoma, Hpv-Related Vulvar Squamous Cell Carcinoma | phase1AndPhase2 | Active Not Recruiting | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | Aug 17, 2017 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Tg6050 | Phase I | Non-small Cell Lung Cancer | Terminated | A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir) | Mar 15, 2023 | ― |
| Tg4050 | phase1AndPhase2 | Squamous Cell Carcinoma Of Head And Neck | Active Not Recruiting | A Clinical Trial Evaluating TG4050 in Head and Neck Cancer | Nov 21, 2019 | ― |
| Tg4050 | Phase I | Fallopian Tube Cancer, Ovarian Carcinoma, Peritoneal Carcinoma | Completed | A Trial Evaluating TG4050 in Ovarian Carcinoma. | Feb 06, 2019 | ― |
| Avelumab, Tg4001 | phase1AndPhase2 | Hpv-Related Cervical Carcinoma, Hpv-Related Carcinoma, Hpv-Related Anal Squamous Cell Carcinoma, Hpv-Related Penile Squamous Cell Carcinoma, Hpv-Related Vulvar Squamous Cell Carcinoma | Active Not Recruiting | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | Aug 17, 2017 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Transgene SA (DE:TGNA) have in its pipeline
Transgene DE:TGNA is currently developing the following drugs: Tg6050, Tg4050, Avelumab, Tg4001. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
